Genomic control of inflammation in experimental atopic dermatitis
Yan Liu, Jozef Zienkiewicz, Huan Qiao, Katherine N Gibson-Corley, Kelli L Boyd, Ruth Ann Veach, Jacek Hawiger, Yan Liu, Jozef Zienkiewicz, Huan Qiao, Katherine N Gibson-Corley, Kelli L Boyd, Ruth Ann Veach, Jacek Hawiger
Abstract
Atopic Dermatitis (AD) or eczema, a recurrent allergic inflammation of the skin, afflicts 10-20% of children and 5% adults of all racial and ethnic groups globally. We report a new topical treatment of AD by a Nuclear Transport Checkpoint Inhibitor (NTCI), which targets two nuclear transport shuttles, importin α5 and importin β1. In the preclinical model of AD, induced by the active vitamin D3 analog MC903 (calcipotriol), NTCI suppressed the expression of keratinocyte-derived cytokine, Thymic Stromal Lymphopoietin (TSLP), the key gene in AD development. Moreover, the genes encoding mediators of TH2 response, IL-4 and its receptor IL-4Rα were also silenced together with the genes encoding cytokines IL-1β, IL-6, IL-13, IL-23α, IL-33, IFN-γ, GM-CSF, VEGF A, the chemokines RANTES and IL-8, and intracellular signal transducers COX-2 and iNOS. Consequently, NTCI suppressed skin infiltration by inflammatory cells (eosinophils, macrophages, and CD4 + T lymphocytes), and reduced MC903-evoked proliferation of Ki-67-positive cells. Thus, we highlight the mechanism of action and the potential utility of topical NTCI for treatment of AD undergoing Phase 1/2 clinical trial (AMTX-100 CF, NCT04313400).
Conflict of interest statement
Y.L., J.Z., R.A.V., and J.H. are coinventors of patents assigned to Vanderbilt University and the US Department of Veterans Affairs. J.H. cofounded Amytrx Therapeutics, Inc. Other authors have declared no conflict of interest.
© 2022. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Figures
References
- Nutten S. Atopic dermatitis: Global epidemiology and risk factors. Ann. Nutr. Metab. 2015;66(Suppl 1):8–16. doi: 10.1159/000370220.
- Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J. Allergy Clin. Immunol. 2017;139(4S):S65–S76. doi: 10.1016/j.jaci.2017.01.011.
- Kaufman BP, Guttman-Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic groups-Variations in epidemiology, genetics, clinical presentation and treatment. Exp. Dermatol. 2018;27(4):340–357. doi: 10.1111/exd.13514.
- Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat. Rev. Dis. Primers. 2018;4(1):1. doi: 10.1038/s41572-018-0001-z.
- Gottlieb AB. Therapeutic options in the treatment of psoriasis and atopic dermatitis. J. Am. Acad. Dermatol. 2005;53(1 Suppl 1):S3–16. doi: 10.1016/j.jaad.2005.04.026.
- Beck LA, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N. Engl. J. Med. 2014;371(2):130–139. doi: 10.1056/NEJMoa1314768.
- Hawiger J, Zienkiewicz J. Decoding inflammation, its causes, genomic responses, and emerging countermeasures. Scand. J. Immunol. 2019;90(6):e12812. doi: 10.1111/sji.12812.
- Schoepe S, Schacke H, May E, Asadullah K. Glucocorticoid therapy-induced skin atrophy. Exp. Dermatol. 2006;15(6):406–420. doi: 10.1111/j.0906-6705.2006.00435.x.
- Zienkiewicz J, Armitage A, Hawiger J. Targeting nuclear import shuttles, importins/karyopherins alpha by a peptide mimicking the NFkappaB1/p50 nuclear localization sequence. J. Am. Heart Assoc. 2013;2(5):e000386. doi: 10.1161/JAHA.113.000386.
- Liu Y, et al. Nuclear transport modulation reduces hypercholesterolemia, atherosclerosis, and fatty liver. J. Am. Heart Assoc. 2013;2(2):e000093. doi: 10.1161/JAHA.113.000093.
- Li M, et al. Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis. Proc. Natl. Acad. Sci. USA. 2006;103(31):11736–11741. doi: 10.1073/pnas.0604575103.
- Gilhar A, et al. Mouse models of atopic dermatitis: A critical reappraisal. Exp. Dermatol. 2021;30(3):319–336. doi: 10.1111/exd.14270.
- Li M, et al. Induction of thymic stromal lymphopoietin expression in keratinocytes is necessary for generating an atopic dermatitis upon application of the active vitamin D3 analogue MC903 on mouse skin. J. Invest. Dermatol. 2009;129(2):498–502. doi: 10.1038/jid.2008.232.
- Marschall P, et al. Dual function of Langerhans cells in skin TSLP-promoted TFH differentiation in mouse atopic dermatitis. J. Allergy Clin. Immunol. 2021;147(5):1778–1794. doi: 10.1016/j.jaci.2020.10.006.
- Kubo A, Nagao K, Amagai M. Epidermal barrier dysfunction and cutaneous sensitization in atopic diseases. J. Clin. Invest. 2012;122(2):440–447. doi: 10.1172/JCI57416.
- Jiang, Y., et al. Cytokinocytes: the diverse contribution of keratinocytes to immune responses in skin. JCI Insight.5(20) (2020).
- Liu Y, et al. Hyperlipidemic hypersensitivity to lethal microbial inflammation and its reversal by selective targeting of nuclear transport shuttles. Sci. Rep. 2021;11(1):11907. doi: 10.1038/s41598-021-91395-w.
- Ebner S, et al. Thymic stromal lymphopoietin converts human epidermal Langerhans cells into antigen-presenting cells that induce proallergic T cells. J. Allergy Clin. Immunol. 2007;119(4):982–990. doi: 10.1016/j.jaci.2007.01.003.
- Theoharides TC, et al. IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc. Natl. Acad. Sci. USA. 2010;107(9):4448–4453. doi: 10.1073/pnas.1000803107.
- Waskow C, Bartels S, Schlenner SM, Costa C, Rodewald HR. Kit is essential for PMA-inflammation-induced mast-cell accumulation in the skin. Blood. 2007;109(12):5363–5370. doi: 10.1182/blood-2006-08-039131.
- Torgerson TR, Colosia AD, Donahue JP, Lin YZ, Hawiger J. Regulation of NF-kappa B, AP-1, NFAT, and STAT1 nuclear import in T lymphocytes by noninvasive delivery of peptide carrying the nuclear localization sequence of NF-kappa B p50. J. Immunol. 1998;161(11):6084–6092.
- DiGiandomenico A, et al. The "genomic storm" induced by bacterial endotoxin is calmed by a nuclear transport modifier that attenuates localized and systemic inflammation. PLoS ONE. 2014;9(10):e110183. doi: 10.1371/journal.pone.0110183.
- Bromley SK, Larson RP, Ziegler SF, Luster AD. IL-23 induces atopic dermatitis-like inflammation instead of psoriasis-like inflammation in CCR2-deficient mice. PLoS ONE. 2013;8(3):e58196. doi: 10.1371/journal.pone.0058196.
- Steinhoff M, Schmelz M, Szabo IL, Oaklander AL. Clinical presentation, management, and pathophysiology of neuropathic itch. Lancet Neurol. 2018;17(8):709–720. doi: 10.1016/S1474-4422(18)30217-5.
- Siiskonen H, Harvima I. Mast cells and sensory nerves contribute to neurogenic inflammation and pruritus in chronic skin inflammation. Front Cell Neurosci. 2019;13:422. doi: 10.3389/fncel.2019.00422.
- Wilson SR, et al. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell. 2013;155(2):285–295. doi: 10.1016/j.cell.2013.08.057.
- Ben-Yaakov K, et al. Axonal transcription factors signal retrogradely in lesioned peripheral nerve. EMBO J. 2012;31(6):1350–1363. doi: 10.1038/emboj.2011.494.
- Poli V. The role of C/EBP isoforms in the control of inflammatory and native immunity functions. J. Biol. Chem. 1998;273(45):29279–29282. doi: 10.1074/jbc.273.45.29279.
- Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 1999;340(6):448–454. doi: 10.1056/NEJM199902113400607.
- Aksentijevich I, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 2009;360(23):2426–2437. doi: 10.1056/NEJMoa0807865.
- Schwartz C, et al. Spontaneous atopic dermatitis in mice with a defective skin barrier is independent of ILC2 and mediated by IL-1β. Allergy. 2019;74(10):1920–1933. doi: 10.1111/all.13801.
- Furue M. Regulation of skin barrier function via competition between AHR Axis versus IL-13/IL-4JAKSTAT6/STAT3 Axis: pathogenic and therapeutic implications in atopic dermatitis. J. Clin. Med. 2020;9(11):3741. doi: 10.3390/jcm9113741.
- Hawiger, J. & Zienkiewicz, J. Endothelial cytoprotection in metabolic and microbial inflammation underlying cardiovascular diseases. Cardiovasc. Res. (2022) - under review
- Briot A, et al. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J. Exp. Med. 2009;206(5):1135–1147. doi: 10.1084/jem.20082242.
- Ong PY, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 2002;347(15):1151–1160. doi: 10.1056/NEJMoa021481.
- Lehmann HS, Heaton T, Mallon D, Holt PG. Staphylococcal enterotoxin-B-mediated stimulation of interleukin-13 production as a potential aetiologic factor in eczema in infants. Int. Arch. Allergy Immunol. 2004;135(4):306–312. doi: 10.1159/000082324.
- Liu D, et al. Suppression of staphylococcal enterotoxin B-induced toxicity by a nuclear import inhibitor. J. Biol. Chem. 2004;279(18):19239–19246. doi: 10.1074/jbc.M313442200.
- Liu D, Zienkiewicz J, DiGiandomenico A, Hawiger J. Suppression of acute lung inflammation by intracellular peptide delivery of a nuclear import inhibitor. Mol. Ther. 2009;17(5):796–802. doi: 10.1038/mt.2009.18.
- Silverberg JI, Paller AS. Association between eczema and stature in 9 US population-based studies. JAMA Dermatol. 2015;151(4):401–409. doi: 10.1001/jamadermatol.2014.3432.
- Grundy SM, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler. Thromb. Vasc. Biol. 2004;24(2):e13–18.
- Kim D, Kobayashi T, Nagao K. Research techniques made simple: Mouse models of atopic dermatitis. J. Invest. Dermatol. 2019;139(5):984–990.e1. doi: 10.1016/j.jid.2019.02.014.
Source: PubMed